This article is more than 5 years old. Information may no longer be current.
Dexamethasone/povidone iodine promising against adenoviral conjunctivitis
Click Here to Manage Email Alerts
A dexamethasone/povidone-iodine ophthalmic suspension may be appropriate treatment for adenoviral conjunctivitis in adults, according to researchers at the Association for Research and Vision in Ophthalmology annual meeting.
The multicenter, randomized, double-masked parallel-group, active- and vehicle-controlled phase 2 study included 124 adults randomized to 0.1% dexamethasone/0.6% povidone-iodine (PVP-I) suspension or vehicle.
One drop of the treatment was applied to both eyes four times daily for 5 days.
After the 5 days, clinical resolution and adenoviral eradication in the primary study eye on day 6 were greater with dexamethasone/PVP-I compared with the vehicle.
“This study indicated that dexamethasone/PVP-I was safe and well tolerated for the treatment of adenoviral conjunctivitis and had significantly better outcomes with respect to both clinical resolution and adenoviral eradication compared to vehicle,” study co-author Abhijit Narvekar, MS, MBBS, said in an interview with Primary Care Optometry News.
“Results of this study showed that after 5 days of topical ocular dexamethasone/PVP-I treatment, rate of clinical resolution was significantly higher compared to vehicle, and higher rate of adenoviral eradication compared to vehicle was observed in as early as 3 days,” he concluded.
To further the clinical development of this investigational treatment, confirmatory phase 3 studies have been initiated, Narvekar added. – by Abigail Sutton
Reference:
Haque RM, et al. Efficacy and safety of dexamethasone/povidone-iodine ophthalmic suspension in adenoviral conjunctivitis. Presented at: Association for Research and Vision in Ophthalmology annual meeting; May 7-11, 2017; Baltimore.
Disclosure: Haque is employed by Shire. Please see the abstract for remaining authors’ financial disclosures.